All In Biotech

NDA 019101 · Hikma

Fentanyl Citrate

Fentanyl Citrate · Injection

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jul 11, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,750

243 Phase 3, 113 recruiting

FAERS reports

17,840

15,772 serious, 6,175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL CITRATE INJECTION Addiction, Abuse, and Misuse Because the use of Fentanyl Citrate Injection exposes patients and other users to the risks of opioid addiction, abuse and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Fentanyl Citrate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Fentanyl Citrate Injection are essential [see Warnings and Precautions ( 5.2 )] . Risks From Concomitant Use With Benzodiazepines Or Other CNS...

What it is approved for

From the label in effect Oct 23, 2026.

Fentanyl Citrate Injection is indicated for: analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises. use as a narcotic analgesic supplement in general or regional anesthesia. administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia. use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures. Fentanyl Citrate Injection is indicated for: analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises. use as an opioid analgesic supplement in general or regional anesthesia. administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia. use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.

Mechanism: Fentanyl Citrate Injection is an opioid agonist, whose principal actions of therapeutic value are analgesia and sedation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 11, 1984 Original approval
2 products under this application
  • FENTANYL CITRATE · FENTANYL CITRATE EQ 0.025MG BASE/0.5ML · INJECTABLE, INJECTION · Discontinued
  • FENTANYL CITRATE · FENTANYL CITRATE EQ 0.05MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Fentanyl" as an intervention, any sponsor and status, largest first.

All 1,750 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dependence3,935
  • overdose2,456
  • death2,065
  • drug abuse1,737
  • toxicity to various agents1,385
  • ill-defined disorder1,288
  • cardiac arrest918
  • respiratory arrest737
  • drug ineffective715
  • drug hypersensitivity628
  • nausea607
  • pain574

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200472
2005115
2006235
2007154
2008261
2009272
20101,148
2011563
2012696
2013404
2014429
2015510
2016595
20171,230
20181,319
20191,207
20201,031
2021760
2022834
20234,700
2024599
2025432
2026272

Recalls

2 FDA enforcement reports for this application.

  • May 13, 2015 · Class III · Terminated

    Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).

  • Feb 16, 2015 · Class III · Terminated

    Failed Impurities/Degradation Specifications; 12 month stability testing.

Shortages

FDA's drug shortage list.

  • Current · updated Oct 14, 2026

    Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fentanyl Citrate (Fentanyl Citrate)

2024 spending

$886K

Beneficiaries

59

510 claims

Per beneficiary

$15,016

$13.76 per unit

View as table
YearSpending
2020$1,457,692
2021$1,366,922
2022$1,233,015
2023$1,389,859
2024$885,973

Part D: Fentanyl Citrate* (Fentanyl Citrate/PF)

2024 spending

$53K

Beneficiaries

13,577

15,510 claims

Per beneficiary

$4

$1.61 per unit

View as table
YearSpending
2020$17,226
2021$38,448
2022$65,012
2023$72,933
2024$53,186

Part B: Fentanyl Citrate (Fentanyl Citrate/PF) · HCPCS J3010

2024 spending

$181K

Beneficiaries

37,082

50,336 claims

Per beneficiary

$5

2024 ASP limit $0.93 per unit

View as table
YearSpending
2020$400,962
2021$290,935
2022$274,248
2023$261,592
2024$180,781

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,032 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.